Original Article
Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death
N Engl J Med 2009; 360:225-235January 15, 2009
- Abstract
Background
Users of typical antipsychotic drugs have an increased risk of serious ventricular arrhythmias and sudden cardiac death. However, less is known regarding the cardiac safety of the atypical antipsychotic drugs, which have largely replaced the older agents in clinical practice.
Methods
We calculated the adjusted incidence of sudden cardiac death among current users of antipsychotic drugs in a retrospective cohort study of Medicaid enrollees in Tennessee. The primary analysis included 44,218 and 46,089 baseline users of single typical and atypical drugs, respectively, and 186,600 matched nonusers of antipsychotic drugs. To assess residual confounding related to factors associated with the use of antipsychotic drugs, we performed a secondary analysis of users of antipsychotic drugs who had no baseline diagnosis of schizophrenia or related psychoses and with whom nonusers were matched according to propensity score (i.e., the predicted probability that they would be users of antipsychotic drugs).
Results
Current users of typical and of atypical antipsychotic drugs had higher rates of sudden cardiac death than did nonusers of antipsychotic drugs, with adjusted incidence-rate ratios of 1.99 (95% confidence interval [CI], 1.68 to 2.34) and 2.26 (95% CI, 1.88 to 2.72), respectively. The incidence-rate ratio for users of atypical antipsychotic drugs as compared with users of typical antipsychotic drugs was 1.14 (95% CI, 0.93 to 1.39). Former users of antipsychotic drugs had no significantly increased risk (incidence-rate ratio, 1.13; 95% CI, 0.98 to 1.30). For both classes of drugs, the risk for current users increased significantly with an increasing dose. Among users of typical antipsychotic drugs, the incidence-rate ratios increased from 1.31 (95% CI, 0.97 to 1.77) for those taking low doses to 2.42 (95% CI, 1.91 to 3.06) for those taking high doses (P<0.001). Among users of atypical agents, the incidence-rate ratios increased from 1.59 (95% CI, 1 .03 to 2.46) for those taking low doses to 2.86 (95% CI, 2.25 to 3.65) for those taking high doses (P=0.01). The findings were similar in the cohort that was matched for propensity score.
Conclusions
Current users of typical and of atypical antipsychotic drugs had a similar, dose-related increased risk of sudden cardiac death.
Media in This Article
Figure 1
Adjusted Incidence-Rate Ratios for Sudden Cardiac Death among Current Users of Antipsychotic Drugs, According to Type of Drug and Dose.Figure 2
Adjusted Incidence-Rate Ratios for Sudden Cardiac Death among Current Users of Six Frequently Prescribed Antipsychotic Drugs, According to Dose.Article Activity
- Article
There are extensive data linking the typical antipsychotic drugs to an increased risk of sudden cardiac death. These medications block repolarizing potassium currents in vitro1,2, and prolong the QT interval, 1,3,4 one important causal mechanism for the ventricular tachyarrhythmias that often lead to sudden cardiac death.5 There are numerous case reports of torsades de pointes and sudden death in conjunction with the use of the typical antipsychotic drugs.6,7 Controlled epidemiologic studies have shown a dose-related increased risk of sudden cardiac death associated with the use of these medications.8-11 Indeed, thioridazine, once one of the most frequently prescribed antipsychotic drugs, now carries a black-box warning of an increased risk of cardiac arrhythmias and sudden death.12
Less is known about the cardiac safety of the atypical antipsychotic drugs, which have largely replaced the older agents in clinical practice. Several atypical antipsychotic drugs block repolarizing potassium currents2 and prolong ventricular repolarization,1,13 and the electrophysiological effects of some of these drugs are similar to those of the older agents. However, although torsades de pointes has been reported in persons using atypical antipsychotic drugs,14-16 whether these drugs increase the risk of sudden cardiac death to the same extent as the older medications is unknown. We therefore conducted a large retrospective cohort study that was designed to compare the risk of sudden cardiac death associated with the use of the two classes of antipsychotic drugs.
Methods
Primary Cohort
We obtained the study data from computerized files of Tennessee Medicaid, which have been used extensively for pharmacoepidemiologic research.17,18 Each person-day of Medicaid enrollment from January 1, 1990, through December 31, 2005 (the study period), was evaluated to determine whether it qualified for inclusion in the analysis. The cohort was restricted to persons 30 to 74 years of age, because among persons younger than 30, sudden cardiac death is very rare and may have a different cause,19 and among persons older than 74, we found death certificates to be less reliable for identifying sudden cardiac deaths. Inclusion in the cohort required the person to have been enrolled in Tennessee Medicaid for at least 730 days (gaps of <7 days were allowed) and to have been eligible for full pharmacy benefits and made regular use of medical care (defined as having had at least one filled prescription and one outpatient visit in each of the 2 preceding years). Patients at high risk for death from noncardiac causes were excluded from the cohort (see Appendix 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).
The cohort included every eligible Medicaid enrollee with at least 1 qualifying day of use of antipsychotic drugs during the study period. The first day of follow-up was defined as the first qualifying day. The cohort also included two controls for each user of antipsychotic drugs, matched for age, sex, and first day of follow-up, who were randomly selected from qualifying nonusers of antipsychotic drugs on the first day of follow-up.
Follow-up extended from the first qualifying day until the end of the study period, the death of the person, the termination of Medicaid enrollment, or the date on which eligibility criteria for inclusion in the cohort were no longer met. Controls could become users of antipsychotic drugs, and patients who left the cohort could reenter it. The follow-up time did not include time during hospitalization and the 30 days after discharge from the hospital because in-hospital deaths were not considered to be study end points and Medicaid files do not include drugs dispensed in the hospital.
The Vanderbilt Committee for the Protection of Human Subjects approved the study and waived the requirement for informed consent. Tennessee's Bureau of TennCare and Department of Health also approved the study. The study was funded by grants from federal agencies, which had no role in study conduct or reporting.
Cohort Matched for Propensity Score
To assess residual confounding by factors associated with the use of antipsychotic drugs, we performed a secondary analysis, using propensity scores20 (i.e., the predicted probability that a person would be a user of antipsychotic drugs) to identify a nonuser control group with a similar psychiatric-illness profile. This matched cohort excluded users of antipsychotic drugs who had a diagnosis of schizophrenia or related psychosis in the 730 days before the first day of follow-up, since treatment with antipsychotic drugs is the standard of care for these conditions. Thus, this group of qualifying users of antipsychotic drugs primarily had mood disorders (a growing reason for the use of antipsychotic drugs), for which there are alternative medications. For each qualifying user, up to two controls were adaptively matched for propensity score (i.e., controls were selected so as to reduce differences in running mean propensity scores) (Appendix 1 in the Supplementary Appendix), within strata defined by the first day of follow-up, birth year, sex, and a marker of severe psychiatric illness (previous hospitalization for psychiatric cause, diagnosis of bipolar disorder, or lithium therapy).
Exposure to Antipsychotic Drugs and Other Medications
Antipsychotic drugs and other study medications were identified from Medicaid pharmacy files. Data in the files included the date the prescription was dispensed, the drug, the quantity, the dose, and the number of days of supply (edited to resolve infrequent discrepancies with quantity). Computerized pharmacy records are an excellent source of medication data because they are not subject to information bias17 and have high concordance with medication use as reported by patients.21-23 The residual misclassification should be limited, and any bias is likely to be in favor of the null hypothesis.17
Each person-day of study follow-up was classified according to the probable use of antipsychotic drugs. Current use included the interval between the time the person filled the prescription and the end of the days of supply (up to a 7-day carryover from previous prescriptions), when the person was most likely to be taking the drug. Indeterminate use included the period up to 90 days after the last current use, and former use included any subsequent person-time that was not classified as current or indeterminate use. Nonuse referred to person-days with no prescribed use of antipsychotic drugs on those days or at any time in the past. Current use was further classified according to the doses of the drugs, which were expressed as approximate equivalents of 100 mg of chlorpromazine (Appendix 1 in the Supplementary Appendix)24,25 and then categorized as low-dose (<100 mg), moderate-dose (100 to 299 mg), or high-dose (≥300 mg). The individual drugs that were analyzed were thioridazine and haloperidol, the most frequently prescribed typical agents, as well as atypical antipsychotic drugs with 3000 person-years or more of current use in the primary cohort (for which ≥5 cases of sudden death were expected under the null hypothesis): clozapine, quetiapine, olanzapine, and risperidone.
Study End Point
The study end point was sudden cardiac death occurring in the community.26-28 Sudden cardiac death was defined as a sudden pulseless condition that was fatal, that was consistent with a ventricular tachyarrhythmia, and that occurred in the absence of a known noncardiac condition as the proximate cause of the death.27 The end point excluded deaths of patients who had been admitted to the hospital, deaths that were not sudden, and deaths for which there was evidence of an extrinsic cause (e.g., drug overdose), a noncardiac cause (e.g., pneumonia), or a cardiac cause that was not consistent with a ventricular tachyarrhythmia (e.g., heart failure).
End points were identified from computerized death certificates linked with computerized Medicaid records. The case definition was developed from and validated by our previous study,8,29,30 in which medical records were reviewed for deaths that occurred between 1988 and 1993. Qualifying deaths occurred outside the hospital or other institution and had an underlying cause of death that our previous study had determined to be compatible with sudden cardiac death (Appendix 1 in the Supplementary Appendix). These deaths were further restricted to those for which there was no evidence of care in the emergency department on the day of death that was inconsistent with care for sudden cardiac death. In our previous study,8 we reviewed medical records for 616 of such qualifying deaths that occurred in the present cohort. Of these deaths, 530 (86.0%) were confirmed cases of sudden cardiac death (unpublished data). As long as the accuracy of the definition of sudden cardiac death did not vary according to the use of antipsychotic drugs, the residual misclassification should bias the results toward the null hypothesis.31
Statistical Analysis
The relative risk of sudden cardiac death according to current use, former use, or nonuse of antipsychotic drugs, adjusted for dose (Appendix 1 in the Supplementary Appendix), was estimated with the incidence-rate ratio, as calculated from Poisson regression models. The models (Appendix 1 in the Supplementary Appendix) included demographic characteristics and variables reflecting coexisting conditions at baseline and subsequent changes during follow-up. Baseline coexisting conditions included cardiovascular and other somatic disease as well as psychiatric and neurologic illness.
We calculated a summary cardiovascular risk score from the large number of baseline cardiovascular and somatic variables. The variables included prescribed medications and recorded diagnoses, as well as utilization of medical care and a measure of compliance with drugs (Appendix 1 in the Supplementary Appendix) for long-term use. The summary risk score was defined for the entire cohort as the predicted probability of sudden death, conditional on no exposure to antipsychotic drugs (estimated with Poisson regression analysis among nonusers of antipsychotic drugs), and then expressed as 20 equal parts. This technique permits more parsimonious models when there are numerous covariates and facilitates description of baseline cardiovascular risk.32
We performed several supplementary analyses to test key assumptions. These included an analysis that permitted only one cohort entry per person, as well as analyses in which additional baseline and time-dependent variables were included in the model (Appendix 1 in the Supplementary Appendix). The findings were essentially identical to those reported here.
All analyses were performed with the use of SAS software, version 9.0 (SAS Institute). All reported P values are two-sided.
Results
Characteristics of the Study Cohorts
The primary cohort included 93,300 users of antipsychotic drugs and 186,600 matched controls. There were 44,218 and 46,089 users of single typical and atypical antipsychotic drugs, respectively, at cohort entry. The cohort that was matched for propensity score included 67,824 users of antipsychotic drugs and 116,069 nonusers.
In the primary cohort, users and nonusers of antipsychotic drugs had similar baseline demographic characteristics (Table 1Table 1
Baseline Characteristics of Cohort Members, According to Use or Nonuse of Antipsychotic Drugs at Cohort Entry.). The mean age was 45.7 years; 65.2% of the cohort members were women, 70.5% were white, and 56.9% were urban residents. Users of antipsychotic drugs were more likely than nonusers to be enrolled in Medicaid because of disability (62.9% vs. 37.4%), but they had a slightly lower mean baseline cardiovascular risk score (9.2 vs. 9.6 on a scale of 0 to 19, with higher scores indicating increased risk). As expected, users of antipsychotic drugs had a higher prevalence of coexisting psychiatric conditions at baseline than did nonusers; however, there was a substantial prevalence of coexisting conditions, particularly affective disorders, among nonusers as well. In the cohort matched for propensity score, users and nonusers of antipsychotic drugs had identical mean propensity scores and similar baseline rates of coexisting psychiatric conditions.As compared with users of typical antipsychotic drugs, users of atypical antipsychotic drugs were slightly younger, were less likely to be enrolled in Medicaid because of disability, and had a higher baseline cardiovascular risk score (Appendix 2 in the Supplementary Appendix). They also used higher doses of antipsychotic drugs, in part owing to the preponderance of low-dose use for the typical drug thioridazine (53.9% of thioridazine users took low doses). Users of atypical antipsychotic drugs also were less likely to have a diagnosis of schizophrenia than were users of typical antipsychotic drugs (13.5% vs. 27.1%), with the exception of users of clozapine (which is indicated for treatment-resistant psychosis24), of whom 89.1% had a diagnosis of schizophrenia. Users of atypical antipsychotic drugs were more likely to have diagnosed mood disorders than were users of typical drugs (bipolar disorder, 23.3% vs. 12.1%; other mood disorders, 60.2% vs. 36.3%).
Sudden Cardiac Death
During the 1,042,159 person-years of cohort follow-up, there were 1870 sudden cardiac deaths, or 17.9 per 10,000 person-years. The unadjusted rate increased from 4.7 deaths per 10,000 for persons 30 to 34 years of age at baseline to 47.6 per 10,000 for those 70 to 74 years of age and was more than twice as high for men as for women (27.1 vs. 12.9 per 10,000).
Current users of typical antipsychotic drugs had an adjusted rate of sudden cardiac death that was twice that for nonusers (incidence-rate ratio, 1.99; 95% confidence interval [CI], 1.68 to 2.34) (Table 2Table 2
Adjusted Incidence-Rate Ratios for Sudden Cardiac Death, According to Use or Nonuse of Antipsychotic Drugs.). A similar increased risk was seen for current users of atypical antipsychotic drugs, who had a rate of sudden cardiac death that was more than twice that for nonusers (incidence-rate ratio, 2.26; 95% CI, 1.88 to 2.72) and that did not differ significantly from the rate for users of the typical agents (incidence-rate ratio for users of atypical as compared with users of typical antipsychotic drugs, 1.14; 95% CI, 0.93 to 1.39). The rates of sudden cardiac death for both current users of typical antipsychotic drugs and current users of atypical drugs were greater than those for former users (P<0.001). Former users did not have a significantly increased risk of sudden cardiac death as compared with nonusers (incidence-rate ratio, 1.13; 95% CI, 0.98 to 1.30). Users of each of the six frequently prescribed antipsychotic drugs had a significantly increased rate of sudden cardiac death (Table 2).The risk of sudden cardiac death increased with an increasing dose among current users of typical or atypical antipsychotic drugs (Figure 1Figure 1
Adjusted Incidence-Rate Ratios for Sudden Cardiac Death among Current Users of Antipsychotic Drugs, According to Type of Drug and Dose.). Among users of the typical agents, the incidence-rate ratios increased from 1.31 (95% CI, 0.97 to 1.77) for persons taking low doses to 2.42 (95% CI, 1.91 to 3.06) for those taking high doses (P<0.001 for dose–response relationship). Among users of the atypical drugs, the incidence-rate ratios increased from 1.59 (95% CI, 1.03 to 2.46) for persons taking low doses to 2.86 (95% CI, 2.25 to 3.65) for those taking high doses (P=0.01 for dose–response relationship). There was a dose–response trend for each of the six frequently prescribed drugs (Figure 2Figure 2Adjusted Incidence-Rate Ratios for Sudden Cardiac Death among Current Users of Six Frequently Prescribed Antipsychotic Drugs, According to Dose.), a trend that was significant in the case of thioridazine (P=0.005) and of borderline significance in the case of risperidone (P=0.05). Current users of thioridazine in high doses (≥300 mg) had the greatest increased risk (incidence-rate ratio, 5.05; 95% CI, 3.09 to 8.27).In the cohort matched for propensity score (Table 3Table 3
Adjusted Incidence-Rate Ratios for Sudden Cardiac Death in the Cohort Matched for Propensity Score, According to Use or Nonuse of Antipsychotic Drugs and According to Dose.), both current users of typical antipsychotic drugs and current users of atypical antipsychotic drugs had an increased risk of sudden cardiac death as compared with nonusers, with incidence-rate ratios of 1.84 (95% CI, 1.50 to 2.26) and 1.99 (95% CI, 1.61 to 2.46), respectively. There was a significant dose–response relationship for each class (P<0.001 and P<0.05, respectively). The incidence-rate ratio for users of atypical drugs as compared with users of typical antipsychotic drugs was 1.08 (95% CI, 0.82 to 1.43).We performed several additional analyses to test the robustness of the study findings. To assess the influence of the adverse metabolic effects of long-term use of antipsychotic drugs,12 we performed an analysis that was restricted to data from persons whose cumulative use of the drugs was less than 365 days' duration. The respective incidence-rate ratios for current users of the typical and atypical drugs as compared with nonusers were 1.73 (95% CI, 1.09 to 2.72; P=0.02) and 1.87 (95% CI, 1.29 to 2.73; P=0.001). To assess possible bias from inclusion of persons who used antipsychotic drugs before the beginning of follow-up, which could preferentially eliminate patients who might be susceptible to proarrhythmic effects,33 we analyzed data from cohort members who had not used antipsychotic drugs during the 2 years preceding the first day of follow-up. In this analysis, the respective incidence-rate ratios for current users of typical and atypical antipsychotic drugs as compared with nonusers were 1.74 (95% CI, 1.14 to 2.67; P=0.001) and 1.86 (95% CI, 1.35 to 2.57; P<0.001). To assess the effects of secular trends in the use of antipsychotic drugs and the incidence of sudden cardiac death, we performed an analysis that was restricted to data from 1998 through 2005; the respective incidence-rate ratios for current users of typical and atypical antipsychotic drugs as compared with nonusers were 1.78 (95% CI, 1.35 to 2.35; P<0.001) and 2.03 (95% CI, 1.65 to 2.50; P<0.001).
Discussion
The frequent occurrence of serious movement disorders in persons taking typical antipsychotic drugs limited the use of these drugs.24 Because atypical antipsychotic drugs are less likely to have this adverse effect, they have been considered a safer treatment alternative34 and have rapidly replaced the older drugs in clinical practice. Overall, the use of antipsychotic drugs has increased, with the number of outpatient visits related to the prescription of an antipsychotic drug nearly doubling between 1998 and 2002.34
Although a link between the use of typical antipsychotic drugs and both torsades de pointes and sudden cardiac death has been established,5,35 this risk was thought to be lower with the use of atypical drugs.36 However, the limited data available on the surrogate markers for torsades de pointes — inhibition of the potassium current IKr and prolongation of the QT interval — suggest that commonly used atypical drugs have electrophysiological effects that are similar to those of the typical antipsychotic drugs.1,13 There are now case reports that document the occurrence of torsades de pointes among users of several atypical antipsychotic drugs.14-16 Our data show that in a large retrospective cohort of adults, current users of the atypical antipsychotic drugs had a dose-dependent increase in the risk of sudden cardiac death that was essentially identical to that among users of the typical agents.
The primary limitation of our study is the potential for confounding by factors associated with the use of antipsychotic drugs. For persons with serious mental illness, these factors include cardiovascular and other somatic disease; concurrent use of other proarrhythmic medications; mood disorders; behavioral risk factors, including substance abuse, poor self-care, and smoking; and other effects of mental illness.12 However, both the study design and analysis included several provisions to manage confounding.
We controlled for an extensive set of cardiovascular disease variables. In the Medicaid population studied, users of antipsychotic drugs had a slightly lower baseline prevalence of diagnosed cardiovascular disease than did comparable nonusers, reflecting the fact that many nonusers qualified for Medicaid because of somatic illness. The requirement that cohort members have regular use of medical care, defined by at least one outpatient visit in each of the 2 years before baseline, should reduce the bias from underdiagnosis of cardiovascular disease in patients with mental illness. The analysis also controlled for concurrent use of other proarrhythmic medications, as well as for diagnosed or treated mood disorders.
With regard to behavioral risk factors, the cohort excluded persons with recorded diagnoses of substance abuse and those who did not have regular medical care. Although study data on smoking were limited, the analysis controlled for cardiovascular diseases caused by smoking,37 diseases that mediate much of the increased risk of sudden death. Furthermore, a sensitivity analysis (Appendix 1 in the Supplementary Appendix) suggested that residual confounding by smoking had at most a minor effect on estimates of relative risk. Although unmeasured behavioral factors may influence the study findings, the absence of a significantly increased risk of sudden death among former users of antipsychotic drugs and the marked dose–response relationship are evidence of a drug effect per se.
An analysis of the cohort that was matched for propensity score provided an additional check as to whether the study findings were due to confounding by factors associated with the use of antipsychotic drugs. This cohort excluded persons with a baseline diagnosis of schizophrenia or related psychoses, for whom such confounding is of greatest concern, and had a similar distribution of coexisting psychiatric conditions at baseline among users and nonusers of antipsychotic drugs. Findings were very similar to those for the primary cohort. However, some point estimates of relative risk were slightly lower; these differences, although not significant, underscore the fact that in this observational study residual confounding cannot be entirely ruled out.
Our study did not assess the mechanisms by which either class of antipsychotic drugs increased the risk of sudden cardiac death. Although antipsychotic drugs have long-term adverse cardiovascular effects,12 the risk of sudden death was elevated in an analysis that excluded long-term users, which suggests that acute drug effects are involved. We believe that the most plausible explanation is that antipsychotic drugs increase the risk of serious ventricular arrhythmias, probably through blockade of potassium channels and prolongation of cardiac repolarization. However, other mechanisms may be involved, including autonomic effects, inhibition of other ion channels, and other acute cardiotoxic effects, such as the myocarditis associated with the use of clozapine.38
In conclusion, current users of typical antipsychotic drugs and of atypical antipsychotic drugs in the study cohort had a similar dose-related increased risk of sudden cardiac death. This finding suggests that with regard to this adverse effect, the atypical antipsychotic drugs are no safer than the older drugs.
Supported by grants from the National Heart, Lung, and Blood Institute (HL081707) and the Agency for Healthcare Quality and Research Centers for Education and Research on Therapeutics (cooperative agreement, HS1-0384).
Dr. Ray reports receiving research support from Pfizer and consulting fees from plaintiffs' attorneys in litigation involving rofecoxib and zoledronic acid and from insurance companies regarding rofecoxib and hormone-replacement therapy; and Dr. Stein, consulting fees from insurance companies regarding antipsychotic drugs. No other potential conflict of interest relevant to this article was reported.
We thank the staff of the Tennessee Bureau of TennCare and the Department of Health, who gave us access to the study data.
Source Information
From the Division of Pharmacoepidemiology, Department of Preventive Medicine (W.A.R., K.H.), the Divisions of Rheumatology (C.P.C., C.M.S.), Cardiology (K.T.M.), and Clinical Pharmacology (K.T.M., C.M.S.), Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine; and the Geriatric Research, Education, and Clinical Center, Nashville Veterans Affairs Medical Center (W.A.R.) — both in Nashville.
Address reprint requests to Dr. Ray at the Department of Preventive Medicine, Village at Vanderbilt, Suite 2600, 1501 21st Ave. South, Nashville, TN 37212, or at cindy.naron@vanderbilt.edu.
- References
References
1
Haddad PM ,Anderson IM . Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62:1649-1671
CrossRef | Web of Science | Medline2
Kongsamut S ,Kang J ,Chen XL ,Roehr J ,Rampe D . A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 2002;450:37-41
CrossRef | Web of Science | Medline3
Thomas SH . Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug React Toxicol Rev 1994;13:77-102
Medline4
Reilly JG ,Ayis SA ,Ferrier IN ,Jones SJ ,Thomas HL . QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000;355:1048-1052
CrossRef | Web of Science | Medline5
Roden DM . Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-1022
Full Text | Web of Science | Medline6
Liberatore MA ,Robinson DS . Torsade de pointes: a mechanism for sudden death associated with neuroleptic drug therapy? J Clin Psychopharmacol 1984;4:143-146
CrossRef | Web of Science | Medline7
Darpo B . Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl 2001;3:K70-K80
CrossRef | Web of Science8
Ray WA ,Meredith S ,Thapa PB ,Meador KG ,Hall K ,Murray KT . Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58:1161-1167
CrossRef | Web of Science | Medline9
Straus SM ,Bleumink GS ,Dieleman JP , et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004;164:1293-1297[Erratum, Arch Intern Med 2004;164:1839.]
CrossRef | Web of Science | Medline10
Reilly JG ,Ayis SA ,Ferrier IN ,Jones SJ ,Thomas SH . Thioridazine and sudden unexplained death in psychiatric inpatients. Br J Psychiatry 2002;180:515-522
CrossRef | Web of Science | Medline11
Hennessy S ,Bilker WB ,Knauss JS , et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ 2002;325:1070-1075
CrossRef | Web of Science | Medline12
Zarate CA Jr ,Patel J . Sudden cardiac death and antipsychotic drugs. Arch Gen Psychiatry 2001;58:1168-1171
CrossRef | Web of Science | Medline13
Harrigan EP ,Miceli JJ ,Anziano R , et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-69
CrossRef | Web of Science | Medline14
Vieweg WV ,Schneider RK ,Wood MA . Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. Acta Psychiatr Scand 2005;112:318-322
CrossRef | Web of Science | Medline15
Tei Y ,Morita T ,Inoue S ,Miyata H . Torsades de pointes caused by a small dose of risperidone in a terminally ill cancer patient. Psychosomatics 2004;45:450-451
CrossRef | Web of Science | Medline16
Heinrich TW ,Biblo LA ,Schneider J . Torsades de pointes associated with ziprasidone. Psychosomatics 2006;47:264-268
CrossRef | Web of Science | Medline17
Ray WA ,Griffin MR . Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 1989;129:837-849
Web of Science | Medline18
Ray WA . Population-based studies of adverse drug effects. N Engl J Med 2003;349:1592-1594
Full Text | Web of Science | Medline19
Liberthson RR . Sudden death from cardiac causes in children and young adults. N Engl J Med 1996;334:1039-1044
Full Text | Web of Science | Medline20
Glynn RJ ,Schneeweiss S ,Sturmer T . Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006;98:253-259
CrossRef | Web of Science | Medline21
Landry JA ,Smyer MA ,Tubman JG ,Lago DJ ,Roberts J ,Simonson W . Validation of two methods of data collection of self-reported medicine use among the elderly. Gerontologist 1988;28:672-676
CrossRef | Web of Science | Medline22
West SL ,Savitz DA ,Koch G ,Strom BL ,Guess HA ,Hartzema A . Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995;142:1103-1112
Web of Science | Medline23
Johnson RE ,Vollmer WM . Comparing sources of drug data about the elderly. J Am Geriatr Soc 1991;39:1079-1084
Web of Science | Medline24
Drug evaluations annual 1995. Chicago: American Medical Association, 1995.
25
Woods SW . Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667
CrossRef | Web of Science | Medline26
Marcus FI ,Cobb LA ,Edwards JE , et al. Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after acute myocardial infarction. Am J Cardiol 1988;61:8-15
CrossRef | Web of Science | Medline27
Siscovick DS ,Raghunathan TE ,Psaty BM , et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994;330:1852-1857
Full Text | Web of Science | Medline28
Albert CM ,Hennekens CH ,O'Donnell CJ , et al. Fish consumption and risk of sudden cardiac death. JAMA 1998;279:23-28
CrossRef | Web of Science | Medline29
Ray WA ,Meredith S ,Thapa PB ,Hall K ,Murray KT . Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004;75:234-241
CrossRef | Web of Science | Medline30
Ray WA ,Murray KT ,Meredith S ,Narasimhulu SS ,Hall K ,Stein CM . Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089-1096
Full Text | Web of Science | Medline31
Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. New York: Van Nostrand Reinhold, 1982.
32
Arbogast PG ,Kaltenbach L ,Ding H ,Ray WA . Adjustment of multiple cardiovascular risk factors using a summary risk score. Epidemiology 2007;19:30-37
CrossRef | Web of Science33
Ray WA . Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-920
CrossRef | Web of Science | Medline34
Aparasu RR ,Bhatara V ,Gupta S . U.S. national trends in the use of antipsychotics during office visits, 1998-2002. Ann Clin Psychiatry 2005;17:147-152
CrossRef | Medline35
Flockhart DA ,Drici MD ,Kerbusch T , et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 2000;20:317-324
CrossRef | Web of Science | Medline36
Glassman AH . Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 2005;66:Suppl:5-10
CrossRef | Web of Science | Medline37
Wilson PW ,D'Agostino RB ,Levy D ,Belanger AM ,Silbershatz H ,Kannel WB . Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847
Web of Science | Medline38
Buckley NA ,Sanders P . Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 2000;23:215-228
CrossRef | Web of Science | Medline
- Citing Articles (141)
Citing Articles
1
Danielle S Cha, Roger S McIntyre. (2012) Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opinion on Pharmacotherapy1-12
CrossRef2
Junzo Watanabe, Yutaro Suzuki, Naoki Fukui, Shin Ono, Takuro Sugai, Nobuto Tsuneyama, Toshiyuki Someya. (2012) Increased Risk of Antipsychotic-Related QT Prolongation During Nighttime. Journal of Clinical Psychopharmacology 32:1, 18-22
CrossRef3
Jennifer M. Polinski, M. Alan Brookhart, Robert J. Glynn, Sebastian Schneeweiss. (2012) Medicare Part D’s Impact on Antipsychotic Drug Use and Costs Among Elderly Patients Without Prior Drug Insurance. Journal of Clinical Psychopharmacology 32:1, 3-10
CrossRef4
J C Bouvy, M A Koopmanschap, R R Shah, H Schellekens. (2012) The Cost-Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies. Clinical Pharmacology & Therapeutics 91:2, 281-288
CrossRef5
Dustin M. Hipp, E. Wesley Ely. (2012) Pharmacological and Nonpharmacological Management of Delirium in Critically Ill Patients. Neurotherapeutics
CrossRef6
Akiko Deguchi, Masayuki Nakamura, Takehiro Hayashi, Akira Sano. (2012) Quetiapine-induced frequent premature ventricular contraction. General Hospital Psychiatry
CrossRef7
V. L. Albaugh, T. C. Vary, O. Ilkayeva, B. R. Wenner, K. P. Maresca, J. L. Joyal, S. Breazeale, T. D. Elich, C. H. Lang, C. J. Lynch. (2012) Atypical Antipsychotics Rapidly and Inappropriately Switch Peripheral Fuel Utilization to Lipids, Impairing Metabolic Flexibility in Rodents. Schizophrenia Bulletin 38:1, 153-166
CrossRef8
Brent T. Mausbach, Susan K. Roepke, Elizabeth A. Chattillion, Alexandrea L. Harmell, Raeanne Moore, Rosa Romero-Moreno, Christopher R. Bowie, Igor Grant. (2012) Multiple mediators of the relations between caregiving stress and depressive symptoms. Aging & Mental Health 16:1, 27-38
CrossRef9
Mubo A. Sonibare, Solomon Umukoro, Esther T. Shonibare. (2012) Antipsychotic property of aqueous and ethanolic extracts of Lonchocarpus cyanescens (Schumach and Thonn.) Benth. (Fabaceae) in rodents. Journal of Natural Medicines 66:1, 127-132
CrossRef10
Steven R. Erickson, Jolene R. Bostwick, Sally K. Guthrie. 2011. Psychological Symptoms Associated with Cardiovascular Drugs; Cardiac Symptoms from Psychiatric Drugs; Drug Interactions. , 194-210.
CrossRef11
Unax Lertxundi, Saioa Domingo Echaburu, Rafael Hernandez Palacios. (2011) The use of antipsychotics in a medium–long stay psychiatric hospital from 1998 to 2010. International Journal of Psychiatry in Clinical Practice1-5
CrossRef12
Michael J Duhig, Sukanta Saha, James G Scott. (2011) Efficacy of risperidone in children with disruptive behavioural disorders. Journal of Paediatrics and Child Healthno-no
CrossRef13
Yuya Mizuno, Robert R. Bies, Gary Remington, David C. Mamo, Takefumi Suzuki, Bruce G. Pollock, Takashi Tsuboi, Koichiro Watanabe, Masaru Mimura, Hiroyuki Uchida. (2011) Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: A cross-sectional study. Progress in Neuro-Psychopharmacology and Biological Psychiatry
CrossRef14
Yutaro Suzuki, Naoki Fukui, Junzo Watanabe, Shin Ono, Takuro Sugai, Nobuto Tsuneyama, Mami Saito, Yoshimasa Inoue, Toshiyuki Someya. (2011) QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone. Human Psychopharmacology: Clinical and Experimentaln/a-n/a
CrossRef15
Jamie L. Geier, Onur N. Karayal, Michael Lewis, John A. Camm, Martin Keane, Charlotte ME. Kremer, Sheela Kolluri, Robert Reynolds, Sybil Eng, Brian L. Strom. (2011) Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC). Pharmacoepidemiology and Drug Safety 20:11, 1192-1198
CrossRef16
Peter Weeke, Fredrik Folke, Gunnar H. Gislason, Freddy K. Lippert, Jonas B. Olesen, Charlotte Andersson, Mads Wissenberg, Henrik E. Poulsen, Søren L. Nielsen, Lars Køber, Christian Torp-Pedersen. (2011) Hospital admissions and pharmacotherapy before out-of-hospital cardiac arrest according to age. Resuscitation
CrossRef17
Robin Nusslock, Ellen Frank. (2011) Subthreshold bipolarity: diagnostic issues and challenges. Bipolar Disorders 13:7-8, 587-603
CrossRef18
J. Brugada. (2011) Psychosis, depression, and high risk for sudden cardiac death: time for co-operation between psychiatrists and cardiologists. European Heart Journal
CrossRef19
Marc De Hert, Johan Detraux, Ruud van Winkel, Weiping Yu, Christoph U. Correll. (2011) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nature Reviews Endocrinology
CrossRef20
Laura A. Bajor, Ana Nectara Ticlea, David N. Osser. (2011) The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Posttraumatic Stress Disorder. Harvard Review of Psychiatry 19:5, 240-258
CrossRef21
A. P. Morrison, P. Hutton, M. Wardle, H. Spencer, S. Barratt, A. Brabban, P. Callcott, T. Christodoulides, R. Dudley, P. French, V. Lumley, S. J. Tai, D. Turkington. (2011) Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial. Psychological Medicine1-8
CrossRef22
J. Honkola, E. Hookana, S. Malinen, K. S. Kaikkonen, M. Juhani Junttila, M. Isohanni, M.-L. Kortelainen, H. V. Huikuri. (2011) Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. European Heart Journal
CrossRef23
Alberto Parabiaghi, Barbara D'Avanzo, Mauro Tettamanti, Angelo Barbato. (2011) The GiSAS study: Rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia. Contemporary Clinical Trials 32:5, 675-684
CrossRef24
Chung-Ting Tsai, Kazuya Ikematsu, Sayaka Sakai, Aya Matsuo, Ichiro Nakasono. (2011) Expression of Bcl2l1, Clcf1, IL-28ra and Pias1 in the mouse heart after single and repeated administration of chlorpromazine. Legal Medicine 13:5, 221-225
CrossRef25
A. Birkhofer, J. Geissendoerfer, P. Alger, A. Mueller, M. Rentrop, T. Strubel, S. Leucht, H. Förstl, K.-J. Bär, G. Schmidt. (2011) The deceleration capacity – a new measure of heart rate variability evaluated in patients with schizophrenia and antipsychotic treatment. European Psychiatry
CrossRef26
Fariba Rajabi, Farhad Hajsheikholeslami, Narges Beyraghi. (2011) Sudden cardiac death after treatment with low dose risperidone in combination with cotrimoxazole. Asian Journal of Psychiatry 4:3, 218-220
CrossRef27
Shaun R. Stauffer. (2011) Progress toward Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 (mGlu 5 ). ACS Chemical Neuroscience 2:8, 450-470
CrossRef28
Ha Jeong-Hoon, Wong Cheuk-Kit. (2011) Pharmacologic treatment of depression in patients with myocardial infarction. Journal of Geriatric Cardiology 8:2, 121-126
CrossRef29
James J. Gugger. (2011) Antipsychotic Pharmacotherapy and Orthostatic Hypotension. CNS Drugs 25:8, 659-671
CrossRef30
T. E. Tungaraza, U. Zahid, B. Venkataramaiah. (2011) Polypharmacy and high-dose antipsychotics at the time of discharge from acute psychiatric wards. The Psychiatrist 35:8, 288-292
CrossRef31
Iria Grande, Alexandre Pons, Immaculada Baeza, Ángela Torras, Miguel Bernardo. (2011) QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment. Human Psychopharmacology: Clinical and Experimentaln/a-n/a
CrossRef32
Maithri Prabhakar, William G Haynes, William H Coryell, Elizabeth A Chrischilles, Del D Miller, Stephan Arndt, Vicki L Ellingrod, Lois Warren, Jess G Fiedorowicz. (2011) Factors Associated with the Prescribing of Olanzapine, Quetiapine, and Risperidone in Patients with Bipolar and Related Affective Disorders. Pharmacotherapy 31:8, 806-812
CrossRef33
J. E. Morley. (2011) Can we improve care for patients with dementia?. The journal of nutrition, health & aging 15:7, 523-526
CrossRef34
Hiroyoshi Takeuchi, Takefumi Suzuki, Hiroyuki Uchida, Toshiaki Kikuchi, Shinichiro Nakajima, Hiroshi Manki, Koichiro Watanabe, Haruo Kashima. (2011) How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review. Journal of Psychiatric Research 45:8, 1083-1088
CrossRef35
Chisa Tsutsumi, Hiroyuki Uchida, Takefumi Suzuki, Koichiro Watanabe, Hiroyoshi Takeuchi, Shinichiro Nakajima, Yoshie Kimura, Yuichiro Tsutsumi, Koichi Ishii, Yasushi Imasaka, Shitij Kapur. (2011) The evolution of antipsychotic switch and polypharmacy in natural practice — A longitudinal perspective. Schizophrenia Research 130:1-3, 40-46
CrossRef36
Erin Schwenger, Jane Dumontet, Mary H.H. Ensom. (2011) Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?. Clinical Pharmacokinetics 50:7, 415-428
CrossRef37
Margaret G Woerner, Christoph U Correll, Jose Ma J Alvir, Blaine Greenwald, Howard Delman, John M Kane. (2011) Incidence of Tardive Dyskinesia with Risperidone or Olanzapine in the Elderly: Results from a 2-Year, Prospective Study in Antipsychotic-Naïve Patients. Neuropsychopharmacology 36:8, 1738-1746
CrossRef38
H. Uchida, T. Suzuki, H. Takeuchi, T. Arenovich, D. C. Mamo. (2011) Low Dose vs Standard Dose of Antipsychotics for Relapse Prevention in Schizophrenia: Meta-analysis. Schizophrenia Bulletin 37:4, 788-799
CrossRef39
Elizabeth A. D. Lee. (2011) Complex Contribution of Combat-Related Post-Traumatic Stress Disorder to Veteran Suicide: Facing an Increasing Challenge. Perspectives in Psychiatric Careno-no
CrossRef40
Maurizio Pompili, Gianluca Serafini, Marco Innamorati, Elisa Ambrosi, Ludovica Telesforo, Paola Venturini, Gloria Giordano, Michele Battuello, David Lester, Paolo Girardi. (2011) Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?. Expert Review of Neurotherapeutics 11:7, 989-1006
CrossRef41
James Innes, Lynda Iyeke. (2011) A review of the practice and position of monitoring in today’s rapid tranquilisation protocols. Journal of Psychiatric Intensive Care1-10
CrossRef42
Jennifer A. Frontera. (2011) Delirium and Sedation in the ICU. Neurocritical Care 14:3, 463-474
CrossRef43
Jimmi Nielsen, Claus Graff, Jørgen K. Kanters, Egon Toft, David Taylor, Jonathan M. Meyer. (2011) Assessing QT Interval Prolongation and its Associated Risks with Antipsychotics. CNS Drugs 25:6, 473-490
CrossRef44
A. J. Mitchell, D. Lawrence. (2011) Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis. The British Journal of Psychiatry 198:6, 434-441
CrossRef45
Kurt Samson. (2011) OIG: Atypical Antipsychotics Overused in Nursing Homes. Neurology Today 11:12, 1
CrossRef46
Takashi Tsuboi, Takefumi Suzuki, Hiroyuki Uchida. (2011) A Tipping Point in Drug Dosing in Late-Life Schizophrenia. Current Psychiatry Reports 13:3, 225-233
CrossRef47
Amir Badshah, Fazal Subhan, Khalid Rauf, Nadeem Irfan Bukhari, Kifayatullah Shah, Samiullah Khan, Zia Ahmed, Ihsanullah Khan. (2011) Development of Controlled-Release Matrix Tablet of Risperidone: Influence of Methocel®- and Ethocel®-Based Novel Polymeric Blend on In Vitro Drug Release and Bioavailability. AAPS PharmSciTech 12:2, 525-533
CrossRef48
Wayne A. Ray. (2011) Improving Automated Database Studies. Epidemiology 22:3, 302-304
CrossRef49
Kathlyn J. Ronaldson, Paul B. Fitzgerald, Andrew J. Taylor, Duncan J. Topliss, John J. McNeil. (2011) Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66 surviving cases. Schizophrenia Research 128:1-3, 161-165
CrossRef50
Paul Howard, Robert Twycross, John Shuster, Mary Mihalyo, Andrew Wilcock. (2011) Antipsychotics. Journal of Pain and Symptom Management 41:5, 956-965
CrossRef51
S Setoguchi, W H Shrank, J Liu, JC Lee, U Saya, W C Winkelmayer, N A Dreyer. (2011) Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: Challenges in Comparative Effectiveness Using Medicare Data. Clinical Pharmacology & Therapeutics 89:5, 674-682
CrossRef52
Thomas W. Meeks, John W. Culberson, Monica S. Horton. (2011) Medications in Long-Term Care: When Less is More. Clinics in Geriatric Medicine 27:2, 171-191
CrossRef53
Anna-Karoline Israel, Andrea Seeck, Michael Karl Boettger, Tobias Rachow, Sandy Berger, Andreas Voss, Karl-Jürgen Bär. (2011) Peripheral endothelial dysfunction in patients suffering from acute schizophrenia: A potential marker for cardiovascular morbidity?. Schizophrenia Research 128:1-3, 44-50
CrossRef54
Cliff McKinney, Kimberly Renk. (2011) Atypical antipsychotic medications in the management of disruptive behaviors in children: Safety guidelines and recommendations. Clinical Psychology Review 31:3, 465-471
CrossRef55
Karen J. Mathewson, Irene E. Drmic, Michelle K. Jetha, Susan E. Bryson, Joel O. Goldberg, Geoffrey B. Hall, Diane L. Santesso, Sidney J. Segalowitz, Louis A. Schmidt. (2011) Behavioral and cardiac responses to emotional stroop in adults with autism spectrum disorders: influence of medication. Autism Research 4:2, 98-108
CrossRef56
Sandhya Mehta, Hua Chen, Michael Johnson, Rajender R. Aparasu. (2011) Risk of Serious Cardiac Events in Older Adults Using Antipsychotic Agents. The American Journal of Geriatric Pharmacotherapy 9:2, 120-132
CrossRef57
Kasey Bowden, Sharon A. Fitzgerald, Ubolrat Piamjariyakul, Marilyn Werkowitch, Noreen C. Thompson, John Keighley, Carol E. Smith. (2011) Comparing Patient and Nurse Specialist Reports of Causative Factors of Depression Related to Heart Failure. Perspectives in Psychiatric Care 47:2, 98-104
CrossRef58
John W. Devlin, Yoanna Skrobik. (2011) Antipsychotics for the Prevention and Treatment of Delirium in the Intensive Care Unit: What Is Their Role?. Harvard Review of Psychiatry 19:2, 59-67
CrossRef59
Carole Parsons, Kate Lapane, Ngaire Kerse, Carmel Hughes. (2011) Prescribing for older people in nursing homes: a review of the key issues. International Journal of Older People Nursing 6:1, 45-54
CrossRef60
Jonas Boström, Niklas Falk, Christian Tyrchan. (2011) Exploiting personalized information for reagent selection in drug design. Drug Discovery Today 16:5-6, 181-187
CrossRef61
Eva Saar, Dimitri Gerostamoulos, Olaf H. Drummer, Jochen Beyer. (2011) Assessment of the stability of 30 antipsychotic drugs in stored blood specimens. Forensic Science International
CrossRef62
Hiroyuki Uchida, David C. Mamo. (2011) Balancing Potential Risks and Benefits of Adjunctive Use of Aripiprazole With Risperidone for the Treatment of Schizophrenia. Journal of Clinical Psychopharmacology 31:1, 136-137
CrossRef63
G. C. Alexander, S. A. Gallagher, A. Mascola, R. M. Moloney, R. S. Stafford. (2011) Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiology and Drug Safety 20:2, 177-184
CrossRef64
John E. Morley. (2011) Alzheimer’s Disease: Future Treatments. Journal of the American Medical Directors Association 12:1, 1-7
CrossRef65
I. Vogel Kahmann, W. Ruppen, G. Lurati Buse, D.A. Tsakiris, M. Bruggisser. (2011) Langzeitmedikation und perioperatives Management. Der Internist 52:1, 89-98
CrossRef66
Alfonso Carvajal, Luis H. Martín Arias, Natalia Jimeno. 2011. Antipsychotic drugs. , 89-123.
CrossRef67
Vasilios G. Masdrakis, George Tzanoulinos, Maria Markatou, Panagiotis Oulis. (2011) Cardiac safety of the electroconvulsive therapy–paliperidone combination: a preliminary study. General Hospital Psychiatry 33:1, 83.e9-83.e10
CrossRef68
Saduf Riaz, Louise Bradley, Khalid Nawab. (2011) Monitoring of Physical Health in Learning Disability Patients on Antipsychotic Treatment in Lanarkshire, Scotland. The British Journal of Development Disabilities 57:112, 53-67
CrossRef69
Susanne Kraemer, Anette Minarzyk, Thomas Forst, Daniel Kopf, Hans-Peter Hundemer. (2011) Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics - results from a German observational study. BMC Psychiatry 11:1, 173
CrossRef70
Coleman Gross, Christine M. Blasey, Robert L. Roe, Joseph K. Belanoff. (2010) Mifepristone Reduces Weight Gain and Improves Metabolic Abnormalities Associated With Risperidone Treatment in Normal Men. Obesity 18:12, 2295-2300
CrossRef71
Peter Weeke, Fredrik Folke, Gunnar H. Gislason, Freddy K. Lippert, Jonas B. Olesen, Charlotte Andersson, Emil L. Fosbøl, Mette G. Charlot, Jørgen K. Kanters, Henrik E. Poulsen, Søren Loumann Nielsen, Lars Køber, Christian Torp-Pedersen. (2010) Pharmacotherapy and hospital admissions before out-of-hospital cardiac arrest: A nationwide study. Resuscitation 81:12, 1657-1663
CrossRef72
Thaddeus Walczak. 2010. Risk Factors for Sudden Death in Epilepsy. .
CrossRef73
A. Raglio, G. Bellelli, D. Traficante, M. Gianotti, M.C. Ubezio, S. Gentile, D. Villani, M. Trabucchi. (2010) Efficacy of music therapy treatment based on cycles of sessions: A randomised controlled trial. Aging & Mental Health 14:8, 900-904
CrossRef74
Thomas J Raedler. (2010) Cardiovascular aspects of antipsychotics. Current Opinion in Psychiatry 23:6, 574-581
CrossRef75
Joseph H. Friedman. (2010) Parkinson’s disease psychosis 2010: A review article. Parkinsonism & Related Disorders 16:9, 553-560
CrossRef76
S. H. L. Thomas, M. D. Drici, G. C. Hall, M. A. Crocq, B. Everitt, M. H. Lader, C. Le. Jeunne, D. Naber, S. Priori, M. Sturkenboom, F. Thibaut, J. Peuskens, A. Mittoux, P. Tanghøj, M. Toumi, N. D. Moore, R. D. Mann. (2010) Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatrica Scandinavica 122:5, 345-355
CrossRef77
Harvey S. Singer. (2010) Treatment of Tics and Tourette Syndrome. Current Treatment Options in Neurology 12:6, 539-561
CrossRef78
Ann Louise Barrick, Philip D. Sloane, Christianna S. Williams, C. Madeline Mitchell, Bettye Rose Connell, Wendy Wood, Susan E. Hickman, John S. Preisser, Sheryl Zimmerman. (2010) Impact of ambient bright light on agitation in dementia. International Journal of Geriatric Psychiatry 25:10, 1013-1021
CrossRef79
Chris J. Bushe, Mauricio Tohen. 2010. Bipolar Disorder and Safety Monitoring for Clinicians: A Review of the Evidence and the Implications. , 367-383.
CrossRef80
Chi-Un Pae, Manmohandeep Singh Sohi, Ho-Jun Seo, Alessandro Serretti, Ashwin A. Patkar, David C. Steffens, Prakash S. Masand. (2010) Quetiapine XR: Current status for the treatment of major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 34:7, 1165-1173
CrossRef81
Bart C. Kleijer, Eibert R. Heerdink, Toine C.G. Egberts, Paul A.F. Jansen, Rob J. van Marum. (2010) Antipsychotic Drug Use and the Risk of Venous Thromboembolism in Elderly Patients. Journal of Clinical Psychopharmacology 30:5, 526-530
CrossRef82
Amir Badshah, Fazal Subhan, Khalid Rauf. (2010) Controlled Release Matrix Tablets of Olanzapine: Influence of Polymers on the In Vitro Release and Bioavailability. AAPS PharmSciTech 11:3, 1397-1404
CrossRef83
Rajiv Tandon, Henry A. Nasrallah, Matcheri S. Keshavan. (2010) Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future. Schizophrenia Research 122:1-3, 1-23
CrossRef84
Catherine B. Johannes, Cristina Varas-Lorenzo, Lisa J. McQuay, Kirk D. Midkiff, Daniel Fife. (2010) Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiology and Drug Safety 19:9, 881-888
CrossRef85
2010. References. , 165-193.
CrossRef86
C. Nordin. (2010) The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 53:8, 1552-1561
CrossRef87
Jae Seung Chang, Cheol Sung Yoo, Sang Hoon Yi, Kye Hyun Hong, Yu-Sang Lee, Hong Seok Oh, Dong Chung Jung, Yong Sik Kim, Yong Min Ahn. (2010) Changes in heart rate dynamics of patients with schizophrenia treated with risperidone. Progress in Neuro-Psychopharmacology and Biological Psychiatry 34:6, 924-929
CrossRef88
J. E. Morley. (2010) Clinical practice in nursing homes as a key for progress. The journal of nutrition, health & aging 14:7, 586-593
CrossRef89
Eva Saar, Dimitri Gerostamoulos, Olaf H. Drummer, Jochen Beyer. (2010) Identification and quantification of 30 antipsychotics in blood using LC-MS/MS. Journal of Mass Spectrometry 45:8, 915-925
CrossRef90
Christopher P Alderman, Dasha Loutchkina, Anita C Abarno. (2010) Psychotropic drug safety issues: continuing vigilance is needed. Expert Review of Clinical Pharmacology 3:4, 427-432
CrossRef91
Rebecca C. Rossom, Thomas S. Rector, Frank A. Lederle, Maurice W. Dysken. (2010) Are All Commonly Prescribed Antipsychotics Associated with Greater Mortality in Elderly Male Veterans with Dementia?. Journal of the American Geriatrics Society 58:6, 1027-1034
CrossRef92
Cecilia P. Chung, Katherine T. Murray, C. Michael Stein, Kathi Hall, Wayne A. Ray. (2010) A computer case definition for sudden cardiac death. Pharmacoepidemiology and Drug Safety 19:6, 563-572
CrossRef93
Daniel Mines. (2010) Commentary on the validation studies of sudden cardiac death and ventricular arrhythmia by Hennessy et al. and Chung et al.. Pharmacoepidemiology and Drug Safety 19:6, 573-575
CrossRef94
Charles E. Leonard, Cristin P. Freeman, Rajat Deo, Craig Newcomb, Stephen E. Kimmel, Brian L. Strom, Warren B. Bilker, Sean Hennessy. (2010) Response to commentary entitled ‘Commentary on the validation studies of sudden cardiac death and ventricular arrhythmia by Hennessy et al. and Chung et al.’. Pharmacoepidemiology and Drug Safety 19:6, 576-576
CrossRef95
Jonny Olsson, Åsa Bergman, Anders Carlsten, Thimothy Oké, Cecilia Bernsten, Ingrid K. Schmidt, Johan Fastbom. (2010) Quality of Drug Prescribing in Elderly People in Nursing Homes and Special Care Units for Dementia. Clinical Drug Investigation 30:5, 289-300
CrossRef96
Samantha A. Hollingworth, Dan J. Siskind, Lisa M. Nissen, Maxine Robinson, Wayne D. Hall. (2010) Patterns of antipsychotic medication use in Australia 2002–2007. Australian and New Zealand Journal of Psychiatry 44:4, 372-377
CrossRef97
Brian Olshansky, Mario Delmar, Gordon F. Tomaselli. (2010) The year in arrhythmias—2009 Part II. Heart Rhythm 7:4, 538-548
CrossRef98
(2010) Aktuell. Psychopraxis 13:2, 36-41
CrossRef99
Manpreet K. Singh, Terence A. Ketter, Kiki D. Chang. (2010) Atypical Antipsychotics for Acute Manic and Mixed Episodes in Children and Adolescents with Bipolar Disorder. Drugs 70:4, 433-442
CrossRef100
Barbara J. Drew, Michael J. Ackerman, Marjorie Funk, W. Brian Gibler, Paul Kligfield, Venu Menon, George J. Philippides, Dan M. Roden, Wojciech Zareba. (2010) Prevention of Torsade de Pointes in Hospital Settings. Journal of the American College of Cardiology 55:9, 934-947
CrossRef101
Eitan Nahshoni, Boris Strasberg, Shula Imbar, Ofer Rotem, Shay Gur, Hagai Hermesh, Abaraham Weizman. (2010) Late potentials in the signal-averaged electrocardiogram in schizophrenia patients maintained on antipsychotic agents. European Neuropsychopharmacology 20:3, 146-152
CrossRef102
Briana Mezuk, Nancy E. Morden, Dara Ganoczy, Edward P. Post, Amy M. Kilbourne. (2010) Anticonvulsant Use, Bipolar Disorder, and Risk of Fracture Among Older Adults in the Veterans Health Administration. American Journal of Geriatric Psychiatry 18:3, 245-255
CrossRef103
Marc De Hert, Christoph U. Correll, Dan Cohen. (2010) Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophrenia Research 117:1, 68-74
CrossRef104
Jessica J. Jalbert, Charles B. Eaton, Susan C. Miller, Kate L. Lapane. (2010) Antipsychotic Use and the Risk of Hip Fracture Among Older Adults Afflicted With Dementia. Journal of the American Medical Directors Association 11:2, 120-127
CrossRef105
Jennifer Rossi, Megan C. Swan, Eric D. Isaacs. (2010) The Violent or Agitated Patient. Emergency Medicine Clinics of North America 28:1, 235-256
CrossRef106
Chloe Leon, Philip Gerretsen, Hiroyuki Uchida, Takefumi Suzuki, Tarek Rajji, David C. Mamo. (2010) Sensitivity to Antipsychotic Drugs in Older Adults. Current Psychiatry Reports 12:1, 28-33
CrossRef107
Stefan Weinmann, Volkmar Aderhold. (2010) Antipsychotic medication, mortality and neurodegeneration: The need for more selective use and lower doses. Psychosis 2:1, 50-69
CrossRef108
Timothy D. Girard, Pratik P. Pandharipande, Shannon S. Carson, Gregory A. Schmidt, Patrick E. Wright, Angelo E. Canonico, Brenda T. Pun, Jennifer L. Thompson, Ayumi K. Shintani, Herbert Y. Meltzer, Gordon R. Bernard, Robert S. Dittus, E Wesley Ely. (2010) Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: The MIND randomized, placebo-controlled trial*. Critical Care Medicine 38:2, 428-437
CrossRef109
J. Langan, P. Shajahan. (2010) Antipsychotic polypharmacy: review of mechanisms, mortality and management. The Psychiatrist 34:2, 58-62
CrossRef110
Arash Ansari, David N. Osser. (2010) The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Bipolar Depression. Harvard Review of Psychiatry 18:1, 36-55
CrossRef111
Alissa A. Thomas, Joseph H. Friedman. (2010) Current Use of Clozapine in Parkinson Disease and Related Disorders. Clinical Neuropharmacology 33:1, 14-16
CrossRef112
&NA;. (2010) Sudden Cardiac Death and Stroke With the Use of Antipsychotic Medications. Journal of Head Trauma Rehabilitation 25:1, 68-70
CrossRef113
Ramón Ramos-Ríos, Manuel Arrojo-Romero, Eduardo Paz-Silva, Fernando Carballal-Calvo, José L. Bouzón-Barreiro, Jorge Seoane-Prado, Rosario Codesido-Barcala, Alicia Crespí-Armenteros, Ramón Fernández-Pérez, Javier D. López-Moríñigo, Ignacio Tortajada-Bonaselt, Francisco J. Diaz, Jose de Leon. (2010) QTc interval in a sample of long-term schizophrenia inpatients. Schizophrenia Research 116:1, 35-43
CrossRef114
Jürgen Gallinat. 2010. Pharmakotherapie. , 267-299.
CrossRef115
W. Victor R. Vieweg, Mark A. Wood, Antony Fernandez, Mary Beatty-Brooks, Mehrul Hasnain, Anand K. Pandurangi. (2009) Proarrhythmic Risk with Antipsychotic and Antidepressant Drugs. Drugs & Aging 26:12, 997-1012
CrossRef116
Alex J. Mitchell. (2009) Do Antipsychotics Cost Lives or Save Lives? Risks Versus Benefits From Large Epidemiological Studies. Journal of Clinical Psychopharmacology 29:6, 517-519
CrossRef117
Dylan P. Murray, Miriam Weiner, Maithri Prabhakar, Jess G. Fiedorowicz. (2009) Mania and mortality: Why the excess cardiovascular risk in bipolar disorder?. Current Psychiatry Reports 11:6, 475-480
CrossRef118
Russell C. Callaghan, Matthew D. Boire, Roberto G. Lazo, Kwame McKenzie, Tony Cohn. (2009) Schizophrenia and the incidence of cardiovascular morbidity: A population-based longitudinal study in Ontario, Canada. Schizophrenia Research 115:2-3, 325-332
CrossRef119
Delmar D. Short, Joanne M. Hawley, Maureen F. McCarthy. (2009) Management of Schizophrenia with Medical Disorders: Cardiovascular, Pulmonary, and Gastrointestinal. Psychiatric Clinics of North America 32:4, 759-773
CrossRef120
Clementine Nordon, Karin Martin-Latry, Laurence de Roquefeuil, Philippe Latry, Bernard Bégaud, Bruno Falissard, Frederic Rouillon, Helene Verdoux. (2009) Risk of Death Related to Psychotropic Drug Use in Older People During the European 2003 Heatwave: A Population-Based Case–Control Study. American Journal of Geriatric Psychiatry 17:12, 1059-1067
CrossRef121
Jae Kennedy, Yu Yu Tien, Lawrence J. Cohen, David Alexander Sclar, Darren Liu, Elizabeth G. Blodgett, Josh Engle. (2009) The association between class of antipsychotic and rates of hospitalization: Results of a retrospective analysis of data from the 2005 medicare current beneficiary survey. Clinical Therapeutics 31:12, 2931-2939
CrossRef122
J. Karagianis, D. Novick, J. Pecenak, J. M. Haro, M. Dossenbach, T. Treuer, W. Montgomery, R. Walton, A. J. Lowry. (2009) Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients*. International Journal of Clinical Practice 63:11, 1578-1588
CrossRef123
Kate Jolly, Michael D. Gammage, Kar Keung Cheng, Peter Bradburn, Miriam V. Banting, Michael J. S. Langman. (2009) Sudden death in patients receiving drugs tending to prolong the QT interval. British Journal of Clinical Pharmacology 68:5, 743-751
CrossRef124
Thomas W. McAllister. (2009) Psychopharmacological Issues in the Treatment of TBI and PTSD. The Clinical Neuropsychologist 23:8, 1338-1367
CrossRef125
David D. Dore, Amal N. Trivedi, Vincent Mor, Joseph H. Friedman, Kate L. Lapane. (2009) Atypical antipsychotic use and risk of fracture in persons with Parkinsonism. Movement Disorders 24:13, 1941-1948
CrossRef126
M. De Hert, J.M. Dekker, D. Wood, K.G. Kahl, R.I.G. Holt, H.-J. Möller. (2009) Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry 24:6, 412-424
CrossRef127
Susan E. Bronskill, Paula A. Rochon, Sudeep S. Gill, Nathan Herrmann, Michael P. Hillmer, Chaim M. Bell, Geoffrey M. Anderson, Thérèse A. Stukel. (2009) The Relationship Between Variations in Antipsychotic Prescribing Across Nursing Homes and Short-Term Mortality. Medical Care 47:9, 1000-1008
CrossRef128
Sara Haack, Angela Seeringer, Petra A Thürmann, Thomas Becker, Julia Kirchheiner. (2009) Sex-specific differences in side effects of psychotropic drugs: genes or gender?. Pharmacogenomics 10:9, 1511-1526
CrossRef129
Neil E. I. Langlois. (2009) Sudden adult death. Forensic Science, Medicine, and Pathology 5:3, 210-232
CrossRef130
Ripu D. Jindal, Matcheri S. Keshavan, Kevin Eklund, Angela Stevens, Debra M. Montrose, Vikram K. Yeragani. (2009) Beat-to-beat heart rate and QT interval variability in first episode neuroleptic-naive psychosis. Schizophrenia Research 113:2-3, 176-180
CrossRef131
Stefan Weinmann, John Read, Volkmar Aderhold. (2009) Influence of antipsychotics on mortality in schizophrenia: Systematic review. Schizophrenia Research 113:1, 1-11
CrossRef132
Denise R. Flinn, Kathleen M. Diehl, Lisa S. Seyfried, Preeti N. Malani. (2009) Prevention, Diagnosis, and Management of Postoperative Delirium in Older Adults. Journal of the American College of Surgeons 209:2, 261-268
CrossRef133
Keming Gao, David V Sheehan, Joseph R Calabrese. (2009) Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Review of Neurotherapeutics 9:8, 1147-1158
CrossRef134
Jessica Robinson-Papp, Kathryn J. Elliott, David M. Simpson. (2009) HIV-related neurocognitive impairment in the HAART era. Current HIV/AIDS Reports 6:3, 146-152
CrossRef135
M Robinson, D Rowett, A Leverton, V Mabbott. (2009) Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors. Pharmacoepidemiology and Drug Safety 18:8, 659-664
CrossRef136
John E. Morley. (2009) Polypharmacy in the Nursing Home. Journal of the American Medical Directors Association 10:5, 289-291
CrossRef137
(2009) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:6, i-x
CrossRef138
Owen S. Surman, A Benedict Cosimi, Andrea DiMartini. (2009) Psychiatric Care of Patients Undergoing Organ Transplantation. Transplantation 87:12, 1753-1761
CrossRef139
(2009) Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. New England Journal of Medicine 360:20, 2136-2138
Full Text140
Neil T. Feldman. (2009) Xyrem® safety: The debate continues. Sleep Medicine 10:4, 405-406
CrossRef141
Schneeweiss, Sebastian, Avorn, Jerry, . (2009) Antipsychotic Agents and Sudden Cardiac Death — How Should We Manage the Risk?. New England Journal of Medicine 360:3, 294-296
Full Text
